Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
Prime editing TINF2 in human hematopoietic stem cells to understand telomere length control and treat dyskeratosis congenita
FY 2023-24
Summary
Pediatric genetic disorders are individually rare but collectively frequent, affecting approximately half a million children in Canada. Dyskeratosis congenita is a rare genetic disease caused by mutations in genes involved in the protection of the distal ends of chromosomes. These distal chromosome regions are called telomeres, and they ensure the integrity of the genetic material. A promising way to understand and treat this disease is to precisely modify the pathogenic DNA sequence in human blood stem cells, a process known as therapeutic genome editing. As part of this postdoctoral research project, I propose to adapt a state-of-the-art genome editing technology called prime editing to identify and characterize new pathogenic mutations to better understand dyskeratosis congenita. I also propose to develop a universal therapeutic prime editing approach to treat all dyskeratosis congenita mutations known to be caused by a defective gene called TINF2 in blood stem cells. More broadly, we foresee that the knowledge gained during this project should facilitate the interrogation of blood stem cells and the development of therapeutic prime editing approaches for severe blood disorders afflicting children.
Department
Program
Banting Postdoctoral Fellowship Program
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
491796
Name
Levesque Sébastien
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Prime editing TINF2 in human hematopoietic stem cells to understand telomere length control and treat dyskeratosis congenita
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Blood Disorders; Crispr-Cas9; Dyskeratosis Congenita; Genetic Diseases; Prime Editing; Telomere Biology Disorders; Therapeutic Genome Editing
Abstract
Pediatric genetic disorders are individually rare but collectively frequent, affecting approximately half a million children in Canada. Dyskeratosis congenita is a rare genetic disease caused by mutations in genes involved in the protection of the distal ends of chromosomes. These distal chromosome regions are called telomeres, and they ensure the integrity of the genetic material. A promising way to understand and treat this disease is to precisely modify the pathogenic DNA sequence in human blood stem cells, a process known as therapeutic genome editing. As part of this postdoctoral research project, I propose to adapt a state-of-the-art genome editing technology called prime editing to identify and characterize new pathogenic mutations to better understand dyskeratosis congenita. I also propose to develop a universal therapeutic prime editing approach to treat all dyskeratosis congenita mutations known to be caused by a defective gene called TINF2 in blood stem cells. More broadly, we foresee that the knowledge gained during this project should facilitate the interrogation of blood stem cells and the development of therapeutic prime editing approaches for severe blood disorders afflicting children.
Competitiondate
202309
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Levesque, Sébastien
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~